Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism

E. S. Knochenhauer, C. Cortet-Rudelli, R. D. Cunnigham, B. A. Conway-Myers, D. Dewailly, Ricardo Azziz

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

A deficiency of 21-hydroxylase activity is one of the most commonly inherited genetic disorders in man, with heterozygosity for CYP21 mutations affecting approximately 1 in 60 of the non-Jewish Caucasian population. We have hypothesized that heterozygosity for CYP21 mutations in women increases their risk of developing clinically evident hyperandrogenism, and that this risk is related to the severity of the mutation of CYP21 and/or the 17- hydroxyprogesterone (17-OHP) response to ACTH stimulation. To test these hypotheses, we studied 38 obligate carriers for 21 -hydroxylase deficiency (i.e. mothers of children with congenital adrenal hyperplasia or nonclassic congenital adreanl hyperplasia), comparing them to 27 weight-, parity-, and age-matched controls. Premenopausal carriers, not receiving hormonal treatment (n = 27), had higher mean total and free testosterone [T; 2.02 ± 0.55 vs. 1.56 ± 0.65 nmol/L (P < 0.007) and 0.018 ± 0.007 vs. 0.012 ± 0.006 nmol/L (P < 0.007), respectively] and lower mean sex hormone-binding globulin (214 ± 62 vs. 277 ± 129 nmol/L; P < 0.03) levels compared to controls. There was no difference in the mean basal levels of dehydroepiandrosterone sulfate, androstenedione (A4), or 17-OHP between carriers and controls. As expected, carriers exhibited higher stimulated and net increment 17-OHP levels than controls [21.1 ± 27.1 vs. 6.2 ± 3.1 nmol/L (P < 0.01) and 19.0 ± 26.5 vs. 4.4 ± 2.8 nmol/L (P < 0.009), respectively]. However, no difference was observed in the response of A4 to ACTH-(1-24) stimulation. Of the 27 carriers studied biochemically, 2(7.4%) had a stimulated 17-OHP value between 30.3-60.6 nmol/L, and 1 (3.7%) had a 17-OHP level above 60.6 nmol/L, suggestive of nonclassic adrenal hyperplasia. Of all carriers studied genetically (n = 36), 50.0% (18 of 36) had 1.33% (12 of 36) had 2, and 16.7% (6 of 36) had 3 or more mutations. In 27.8% (10 of 36) of carriers, the mutations were contiguous, consistent with a large gene conversion. All 38 carriers were examined for historical and physical features of hyperandrogenism. Hirsutism was defined as a Ferriman-Gallwey score of 6 or more, menstrual/ovulatory dysfunction as a history of menstrual cycles of more than 35-day, and hyperandrogenemia as total or free T, A4, and/or dehydroepiandrosterone sulfate levels above the upper 95th percentile of control values. Further, defining functional androgen excess (FAE) as the presence of at least 2 of the 3 hyperandrogenic features, 4 of 38 (10.5%) of carriers appeared to be affected (95% confidence interval, 2.9-24.8%). Assuming an expected prevalence rate of FAE in the general population of 5- 20%, the frequency of FAE among our carriers was not significantly higher than expected. In conclusion, heterozygosity for CYP21 mutations does not appear to increase the risk of clinically evident hyperandrogenism, although carrying the defect was associated with higher mean and free T levels. Finally, due to the low frequency of androgen excess in our heterozygote population, we were unable to correlate the severity of the CYP21 mutation and/or the 17-OHP response to ACTH stimulation with the presence of the phenotype.

Original languageEnglish (US)
Pages (from-to)479-485
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume82
Issue number2
DOIs
StatePublished - Feb 20 1997

Fingerprint

Hyperandrogenism
Steroid 21-Hydroxylase
Androgens
Dehydroepiandrosterone Sulfate
Mutation
Adrenocorticotropic Hormone
Cosyntropin
17-alpha-Hydroxyprogesterone
Gene Conversion
Sex Hormone-Binding Globulin
Androstenedione
Level control
Hyperplasia
Testosterone
Population
Congenital Adrenal Hyperplasia
Hirsutism
Inborn Genetic Diseases
Defects
Heterozygote

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Knochenhauer, E. S., Cortet-Rudelli, C., Cunnigham, R. D., Conway-Myers, B. A., Dewailly, D., & Azziz, R. (1997). Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 82(2), 479-485. https://doi.org/10.1210/jc.82.2.479

Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. / Knochenhauer, E. S.; Cortet-Rudelli, C.; Cunnigham, R. D.; Conway-Myers, B. A.; Dewailly, D.; Azziz, Ricardo.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 2, 20.02.1997, p. 479-485.

Research output: Contribution to journalArticle

Knochenhauer, ES, Cortet-Rudelli, C, Cunnigham, RD, Conway-Myers, BA, Dewailly, D & Azziz, R 1997, 'Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism', Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 2, pp. 479-485. https://doi.org/10.1210/jc.82.2.479
Knochenhauer ES, Cortet-Rudelli C, Cunnigham RD, Conway-Myers BA, Dewailly D, Azziz R. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. Journal of Clinical Endocrinology and Metabolism. 1997 Feb 20;82(2):479-485. https://doi.org/10.1210/jc.82.2.479
Knochenhauer, E. S. ; Cortet-Rudelli, C. ; Cunnigham, R. D. ; Conway-Myers, B. A. ; Dewailly, D. ; Azziz, Ricardo. / Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. In: Journal of Clinical Endocrinology and Metabolism. 1997 ; Vol. 82, No. 2. pp. 479-485.
@article{e47665daa7044ae29b48abed6a91df0e,
title = "Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism",
abstract = "A deficiency of 21-hydroxylase activity is one of the most commonly inherited genetic disorders in man, with heterozygosity for CYP21 mutations affecting approximately 1 in 60 of the non-Jewish Caucasian population. We have hypothesized that heterozygosity for CYP21 mutations in women increases their risk of developing clinically evident hyperandrogenism, and that this risk is related to the severity of the mutation of CYP21 and/or the 17- hydroxyprogesterone (17-OHP) response to ACTH stimulation. To test these hypotheses, we studied 38 obligate carriers for 21 -hydroxylase deficiency (i.e. mothers of children with congenital adrenal hyperplasia or nonclassic congenital adreanl hyperplasia), comparing them to 27 weight-, parity-, and age-matched controls. Premenopausal carriers, not receiving hormonal treatment (n = 27), had higher mean total and free testosterone [T; 2.02 ± 0.55 vs. 1.56 ± 0.65 nmol/L (P < 0.007) and 0.018 ± 0.007 vs. 0.012 ± 0.006 nmol/L (P < 0.007), respectively] and lower mean sex hormone-binding globulin (214 ± 62 vs. 277 ± 129 nmol/L; P < 0.03) levels compared to controls. There was no difference in the mean basal levels of dehydroepiandrosterone sulfate, androstenedione (A4), or 17-OHP between carriers and controls. As expected, carriers exhibited higher stimulated and net increment 17-OHP levels than controls [21.1 ± 27.1 vs. 6.2 ± 3.1 nmol/L (P < 0.01) and 19.0 ± 26.5 vs. 4.4 ± 2.8 nmol/L (P < 0.009), respectively]. However, no difference was observed in the response of A4 to ACTH-(1-24) stimulation. Of the 27 carriers studied biochemically, 2(7.4{\%}) had a stimulated 17-OHP value between 30.3-60.6 nmol/L, and 1 (3.7{\%}) had a 17-OHP level above 60.6 nmol/L, suggestive of nonclassic adrenal hyperplasia. Of all carriers studied genetically (n = 36), 50.0{\%} (18 of 36) had 1.33{\%} (12 of 36) had 2, and 16.7{\%} (6 of 36) had 3 or more mutations. In 27.8{\%} (10 of 36) of carriers, the mutations were contiguous, consistent with a large gene conversion. All 38 carriers were examined for historical and physical features of hyperandrogenism. Hirsutism was defined as a Ferriman-Gallwey score of 6 or more, menstrual/ovulatory dysfunction as a history of menstrual cycles of more than 35-day, and hyperandrogenemia as total or free T, A4, and/or dehydroepiandrosterone sulfate levels above the upper 95th percentile of control values. Further, defining functional androgen excess (FAE) as the presence of at least 2 of the 3 hyperandrogenic features, 4 of 38 (10.5{\%}) of carriers appeared to be affected (95{\%} confidence interval, 2.9-24.8{\%}). Assuming an expected prevalence rate of FAE in the general population of 5- 20{\%}, the frequency of FAE among our carriers was not significantly higher than expected. In conclusion, heterozygosity for CYP21 mutations does not appear to increase the risk of clinically evident hyperandrogenism, although carrying the defect was associated with higher mean and free T levels. Finally, due to the low frequency of androgen excess in our heterozygote population, we were unable to correlate the severity of the CYP21 mutation and/or the 17-OHP response to ACTH stimulation with the presence of the phenotype.",
author = "Knochenhauer, {E. S.} and C. Cortet-Rudelli and Cunnigham, {R. D.} and Conway-Myers, {B. A.} and D. Dewailly and Ricardo Azziz",
year = "1997",
month = "2",
day = "20",
doi = "10.1210/jc.82.2.479",
language = "English (US)",
volume = "82",
pages = "479--485",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism

AU - Knochenhauer, E. S.

AU - Cortet-Rudelli, C.

AU - Cunnigham, R. D.

AU - Conway-Myers, B. A.

AU - Dewailly, D.

AU - Azziz, Ricardo

PY - 1997/2/20

Y1 - 1997/2/20

N2 - A deficiency of 21-hydroxylase activity is one of the most commonly inherited genetic disorders in man, with heterozygosity for CYP21 mutations affecting approximately 1 in 60 of the non-Jewish Caucasian population. We have hypothesized that heterozygosity for CYP21 mutations in women increases their risk of developing clinically evident hyperandrogenism, and that this risk is related to the severity of the mutation of CYP21 and/or the 17- hydroxyprogesterone (17-OHP) response to ACTH stimulation. To test these hypotheses, we studied 38 obligate carriers for 21 -hydroxylase deficiency (i.e. mothers of children with congenital adrenal hyperplasia or nonclassic congenital adreanl hyperplasia), comparing them to 27 weight-, parity-, and age-matched controls. Premenopausal carriers, not receiving hormonal treatment (n = 27), had higher mean total and free testosterone [T; 2.02 ± 0.55 vs. 1.56 ± 0.65 nmol/L (P < 0.007) and 0.018 ± 0.007 vs. 0.012 ± 0.006 nmol/L (P < 0.007), respectively] and lower mean sex hormone-binding globulin (214 ± 62 vs. 277 ± 129 nmol/L; P < 0.03) levels compared to controls. There was no difference in the mean basal levels of dehydroepiandrosterone sulfate, androstenedione (A4), or 17-OHP between carriers and controls. As expected, carriers exhibited higher stimulated and net increment 17-OHP levels than controls [21.1 ± 27.1 vs. 6.2 ± 3.1 nmol/L (P < 0.01) and 19.0 ± 26.5 vs. 4.4 ± 2.8 nmol/L (P < 0.009), respectively]. However, no difference was observed in the response of A4 to ACTH-(1-24) stimulation. Of the 27 carriers studied biochemically, 2(7.4%) had a stimulated 17-OHP value between 30.3-60.6 nmol/L, and 1 (3.7%) had a 17-OHP level above 60.6 nmol/L, suggestive of nonclassic adrenal hyperplasia. Of all carriers studied genetically (n = 36), 50.0% (18 of 36) had 1.33% (12 of 36) had 2, and 16.7% (6 of 36) had 3 or more mutations. In 27.8% (10 of 36) of carriers, the mutations were contiguous, consistent with a large gene conversion. All 38 carriers were examined for historical and physical features of hyperandrogenism. Hirsutism was defined as a Ferriman-Gallwey score of 6 or more, menstrual/ovulatory dysfunction as a history of menstrual cycles of more than 35-day, and hyperandrogenemia as total or free T, A4, and/or dehydroepiandrosterone sulfate levels above the upper 95th percentile of control values. Further, defining functional androgen excess (FAE) as the presence of at least 2 of the 3 hyperandrogenic features, 4 of 38 (10.5%) of carriers appeared to be affected (95% confidence interval, 2.9-24.8%). Assuming an expected prevalence rate of FAE in the general population of 5- 20%, the frequency of FAE among our carriers was not significantly higher than expected. In conclusion, heterozygosity for CYP21 mutations does not appear to increase the risk of clinically evident hyperandrogenism, although carrying the defect was associated with higher mean and free T levels. Finally, due to the low frequency of androgen excess in our heterozygote population, we were unable to correlate the severity of the CYP21 mutation and/or the 17-OHP response to ACTH stimulation with the presence of the phenotype.

AB - A deficiency of 21-hydroxylase activity is one of the most commonly inherited genetic disorders in man, with heterozygosity for CYP21 mutations affecting approximately 1 in 60 of the non-Jewish Caucasian population. We have hypothesized that heterozygosity for CYP21 mutations in women increases their risk of developing clinically evident hyperandrogenism, and that this risk is related to the severity of the mutation of CYP21 and/or the 17- hydroxyprogesterone (17-OHP) response to ACTH stimulation. To test these hypotheses, we studied 38 obligate carriers for 21 -hydroxylase deficiency (i.e. mothers of children with congenital adrenal hyperplasia or nonclassic congenital adreanl hyperplasia), comparing them to 27 weight-, parity-, and age-matched controls. Premenopausal carriers, not receiving hormonal treatment (n = 27), had higher mean total and free testosterone [T; 2.02 ± 0.55 vs. 1.56 ± 0.65 nmol/L (P < 0.007) and 0.018 ± 0.007 vs. 0.012 ± 0.006 nmol/L (P < 0.007), respectively] and lower mean sex hormone-binding globulin (214 ± 62 vs. 277 ± 129 nmol/L; P < 0.03) levels compared to controls. There was no difference in the mean basal levels of dehydroepiandrosterone sulfate, androstenedione (A4), or 17-OHP between carriers and controls. As expected, carriers exhibited higher stimulated and net increment 17-OHP levels than controls [21.1 ± 27.1 vs. 6.2 ± 3.1 nmol/L (P < 0.01) and 19.0 ± 26.5 vs. 4.4 ± 2.8 nmol/L (P < 0.009), respectively]. However, no difference was observed in the response of A4 to ACTH-(1-24) stimulation. Of the 27 carriers studied biochemically, 2(7.4%) had a stimulated 17-OHP value between 30.3-60.6 nmol/L, and 1 (3.7%) had a 17-OHP level above 60.6 nmol/L, suggestive of nonclassic adrenal hyperplasia. Of all carriers studied genetically (n = 36), 50.0% (18 of 36) had 1.33% (12 of 36) had 2, and 16.7% (6 of 36) had 3 or more mutations. In 27.8% (10 of 36) of carriers, the mutations were contiguous, consistent with a large gene conversion. All 38 carriers were examined for historical and physical features of hyperandrogenism. Hirsutism was defined as a Ferriman-Gallwey score of 6 or more, menstrual/ovulatory dysfunction as a history of menstrual cycles of more than 35-day, and hyperandrogenemia as total or free T, A4, and/or dehydroepiandrosterone sulfate levels above the upper 95th percentile of control values. Further, defining functional androgen excess (FAE) as the presence of at least 2 of the 3 hyperandrogenic features, 4 of 38 (10.5%) of carriers appeared to be affected (95% confidence interval, 2.9-24.8%). Assuming an expected prevalence rate of FAE in the general population of 5- 20%, the frequency of FAE among our carriers was not significantly higher than expected. In conclusion, heterozygosity for CYP21 mutations does not appear to increase the risk of clinically evident hyperandrogenism, although carrying the defect was associated with higher mean and free T levels. Finally, due to the low frequency of androgen excess in our heterozygote population, we were unable to correlate the severity of the CYP21 mutation and/or the 17-OHP response to ACTH stimulation with the presence of the phenotype.

UR - http://www.scopus.com/inward/record.url?scp=0031031621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031031621&partnerID=8YFLogxK

U2 - 10.1210/jc.82.2.479

DO - 10.1210/jc.82.2.479

M3 - Article

C2 - 9024240

AN - SCOPUS:0031031621

VL - 82

SP - 479

EP - 485

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -